drugset
drugset / Trial / NCT00385489

Study Evaluating LXR-623 in Healthy Japanese Adults

NCT00385489 ↗

Phase 1 Completed Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety of LXR-623 in healthy Japanese subjects.

Timeline

Start
2006-08
Primary completion
2006-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LXR-623 Small molecule — Oral

Indications

No indication recorded.